vimarsana.com
Home
Live Updates
FDA to consider RSV vaccine for adults in their 50s : vimars
FDA to consider RSV vaccine for adults in their 50s : vimars
FDA to consider RSV vaccine for adults in their 50s
GSK's RSV Vaccine, Arexvy, may soon be extended to adults aged 50-59 as it undergoes priority review by the FDA. If approved, it will be the first RSV vaccine
Related Keywords
,
Extend ,
Espiratory ,
Vaccinations ,
Adults ,
Virus ,